Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
P 3 (1)

Trial Status

Unknown2
Active Not Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT07084246Active Not RecruitingPrimary

Evaluation of the Effectiveness and Safety of Rozetel Tablet in Patients After PCI: A Multi-Center Observational Study

NCT04161001Phase 3UnknownPrimary

Clinical Trail to Evaluate the Efficacy and Safety of DWJ1451

NCT03648801UnknownPrimary

A Post-marketing Surveillance to Assess Safety and Efficacy of Telostop Plus Tab.

Showing all 3 trials

Research Network

Activity Timeline